CD274 and hepatocellular carcinoma: Tyrosine kinase inhibitors (TKIs) including sorafenib and lenvatinib were the first- line therapy for advanced HCC for the last ten years before the approval of the combination of anti-PDL1 antibody;atezolizumab with VEGF inhibitor;evacizumab in 2020 [132].